Re: Limits of predictive models using microarray data for breast cancer clinical treatment outcome.
Open Access
- 21 December 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 97 (24) , 1851-1852
- https://doi.org/10.1093/jnci/dji433
Abstract
The ability to accurately predict outcome to tamoxifen therapy would advance the management of breast cancer. Tamoxifen acts through the estrogen receptor (ER), and ER expression levels are currently the best predictors of response. Last year, Ma et al. ( 1 ) reported a novel biomarker of a two-gene expression ratio (HOXB13 to IL17BR) in 60 patients with ER-positive early-stage breast cancer treated with adjuvant tamoxifen. However, recently, Reid et al. ( 2 ) failed to validate the performance of this two-gene predictor. We would like to point out three problems with the study of Reid et al. ( 2 ) : 1) cohort selection, 2) definition of response, and 3) primer design.Keywords
This publication has 7 references indexed in Scilit:
- Limits of Predictive Models Using Microarray Data for Breast Cancer Clinical Treatment OutcomeJNCI Journal of the National Cancer Institute, 2005
- Development and validation of therapeutically relevant multi-gene biomarker classifiers.JNCI Journal of the National Cancer Institute, 2005
- Molecular Classification of Tamoxifen-Resistant Breast Carcinomas by Gene Expression ProfilingJournal of Clinical Oncology, 2005
- RE: A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifenCancer Cell, 2004
- A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifenPublished by Elsevier ,2004
- Evi27 encodes a novel membrane protein with homology to the IL17 receptorOncogene, 2000
- Assessment of response to therapy in advanced breast cancerPublished by Elsevier ,1978